Document Detail


Role for fibrate therapy in diabetes: evidence before FIELD.
MedLine Citation:
PMID:  16276243     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: Diabetic dyslipidaemia, among the main factors contributing to vascular risk in type 2 diabetes, is characterized by hypertriglyceridaemia, low HDL-cholesterol and increased prevalence of small dense LDL particles. Because fibrates have positive effects on triglycerides, HDL-cholesterol and LDL particle size, they may be an appropriate treatment for diabetic dyslipidaemia. Statins have been shown to diminish significantly the risk for coronary disease in patients with type 2 diabetes, and so what are the real effects of fibrates on cardiovascular risk in type 2 diabetes? RECENT FINDINGS: Although statins reduce the incidence of coronary disease in type 2 diabetes, data from clinical trials demonstrate 'residual' cardiovascular risk in these patients treated with statins. Clinical trials with fibrates show that they are particularly effective in reducing cardiovascular risk in patients with type 2 diabetes/metabolic syndrome and in those exhibiting the lipid abnormalities typical of diabetic dyslipidaemia (elevated triglycerides, low HDL-cholesterol). SUMMARY: Data on the effects of fibrates on cardiovascular risk in diabetes were obtained from subgroup analyses. Thus far, the only study performed specifically in patients with type 2 diabetes is the angiographic Diabetes Atherosclerosis Intervention Study which demonstrated a significant reduction in progression of atherosclerosis in patients receiving fenofibrate, but it was not powered to analyse the effects of fibrates on clinical outcomes. This is why the Fenofibrate Intervention and Event Lowering in Diabetes study is needed; it will provide robust data on the ability of fibrates to reduce cardiovascular risk in patients with type 2 diabetes.
Authors:
Bruno Vergès
Related Documents :
24839613 - Enhanced incretin effects of exendin-4 expressing chimeric plasmid based on two-step tr...
17978603 - Reducing cardiovascular events in high-risk patients: the challenge of managing hyperte...
25330823 - Higher glucose concentrations following protein- and fat-rich meals - the tuebingen gri...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in lipidology     Volume:  16     ISSN:  0957-9672     ISO Abbreviation:  Curr. Opin. Lipidol.     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-11-08     Completed Date:  2008-08-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9010000     Medline TA:  Curr Opin Lipidol     Country:  England    
Other Details:
Languages:  eng     Pagination:  648-51     Citation Subset:  IM    
Affiliation:
Service Endocrinologie, Diabétologie et Maladies Métaboliques, Centre Hospitalier, Universitaire de Dijon, and INSERM U498, Faculté de Médecine, Dijon, France. bruno.verges@chu-dijon.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antilipemic Agents / therapeutic use*
Clofibric Acid / therapeutic use*
Diabetes Mellitus, Type 2 / blood,  drug therapy*
Dyslipidemias / blood,  drug therapy*
Humans
Metabolic Syndrome X / blood,  drug therapy
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 882-09-7/Clofibric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Statin-induced myositis: a commonly encountered or rare side effect?
Next Document:  HDL-raising strategies in the treatment of coronary artery disease: perspectives from the Armed Forc...